JLJane A. Little

Jane A. Little

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jane A. Little has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • RESOLVE to do better

    by Jane A. Little

    Commentary on: Long Title: Phase 3, randomised, placebo‐controlled trial of Voxelotor for the resolution of leg ulcers in sickle cell disease: RESOLVE. Br J Haematol. 2026;209:2252–2263.

  • Open Access

    High‐Altitude Hypoxemia in Adults With Sickle Cell Disease ( SCD )

    by Mofiyin A. Obadina, Sherri Morris, Tara Alin, Barbara LeVarge, Jane A. Little

  • Open Access

    Trajectories of emergency department use among adolescents and young adults with sickle cell disease in North Carolina

    by Samuel R Wilson, Olu Jegede, Sarah Leonard, Tyra C Girdwood, Wei Pan, Daniel Hatch, Camila Reyes, Payal Desai, Jane A Little, Mariam Kayle

    Objectives: Emergency department (ED) utilization among transition age adolescents and young adults (AYAs, 14-30 years old) with SCD is linked to morbidity and mortality. We describe age-related ED utilization and associations with sociodemographic characteristics among AYAs with SCD in North Carolina (NC). Methods: This observational study used the NC Hospital Discharge data (2014-2019). We conducted latent growth class analysis to identify distinct ED utilization trajectories by age and bivariate analyses to explore associations between ED utilization classes and sociodemographic factors. Results: During the study, 3614 AYAs with SCD (54% female; 96% Black) had 39 585 ED visits. The mean number of annual ED visits was 1.23 at age 14, peaking at 5.35 at age 24, and declining to 4.64 at age 30. Three classes of ED utilization trajectories were identified: low [95.2%, mean (SD) annual visits = 2.29 (2.55)], medium [4.1%, mean (SD) annual visits = 20.38 (7.42)], and high [0.7%, mean (SD) annual visits = 47.71 (18.58)]. Despite similar utilization at age 14, medium and high utilization groups had respectively 10 and 20 times the ED utilization of the low utilization group and had visits at multiple EDs. Social vulnerability was not associated with ED utilization. Conclusion: A small fraction of AYAs drive most ED utilization, with significant increases observed during transition. These results underscore the necessity for resources and tailored interventions to enhance care continuity during transition. Further research should identify modifiable factors influencing ED visits and develop strategies to improve transition care.

  • Open Access

    A public health led, statewide approach to improving emergency department care for individuals with sickle cell disease—North Carolina

    by Paula Tanabe, Mariam Kayle, Justin Calhoun, Beng Fuh, Olu Jegede, Jane Little, Elazzoa McArthur, Todd L Savitt, Lauren Siewny, John J Strouse, et al.

    Sickle cell disease (SCD) is a lifelong condition affecting approximately 100 000 individuals in the United States. It causes progressive organ damage through hemolysis, vaso-occlusion, and chronic inflammation. Patients frequently present to emergency departments (EDs) for acute complications, most commonly severe pain episodes. Unfortunately, acute care encounters are often characterized by negative interactions between patients and providers, fostering mutual distrust and dissatisfaction. In response to community input, the North Carolina Governor’s Council on Sickle Cell Syndrome Medical Research Committee partnered with medical centers, the North Carolina Department of Health, and community-based organizations to implement standardized guidelines for SCD care statewide. Using state-level data, the initiative targeted the 20 ED sites with the highest visit volumes. Each site received an implementation toolbox, developed by the committee and designed to improve emergency care. Following formal outreach, expert consultants engaged site representatives to review the toolbox and initiate discussions on best practices, including Emergency Severity Index (ESI) triage protocols and individualized care plans. Monthly expert consultation (committee members) follow-up calls were established to monitor progress and sustain engagement. Additional efforts were directed toward sites that did not initially respond to formal outreach. To further support the care of patients with complex health care needs who receive care at multiple institutions, we established a multi-institutional monthly virtual patient care conference focused on pain management in high needs patients and sites were invited to participate. This initiative reports a public health program to improve ED care for persons living with SCD.

  • Low Use of FDA ‐Approved Medications for Sickle Cell Disease in Adults

    by Joshua G. Rivenbark, Alan C. Kinlaw, Justin G. Trogdon, Jane A. Little

    As the landscape of treatments for sickle cell disease (SCD) shifts, relatively little is known regarding the rates of medication prescription for SCD at a population level. This study was a cross‐sectional annualized cohort analysis that used North Carolina Medicaid claims data from 2018 through 2022 to examine rates of prescription of FDA‐approved medications for SCD and factors associated with their use. Adults with SCD were identified using a standard administrative data algorithm, and their data were aggregated to the person‐year level. Annual prescription rates (≥ 1 claim) of hydroxyurea, L‐glutamine, voxelotor, crizanlizumab, and opioid analgesics were calculated over time, and binomial mixed effects models examined associations between prescription and individual characteristics. Among 1733 individuals, the rate of hydroxyurea prescription ranged from 24.2%–26.7%. Rates for L‐glutamine, voxelotor, and crizanlizumab were less than 6.0% each year. The rate of opioid prescription ranged from 51.4%–53.9%. Seeing a hematologist was consistently associated with higher odds of receiving SCD‐specific medications. Age was associated with decreased prescription of hydroxyurea, L‐glutamine, and opioids, but increased prescription of voxelotor. Males had higher odds of receiving hydroxyurea. Although use of FDA‐approved medications for SCD was low, improved access to hematologists may increase medication utilization.

  • Open Access

    Nocturnal hemoglobin desaturation in chronically transfused adults with sickle cell disease: a retrospective study

    by Mofiyin A Obadina, Iman Owens, Ada Chang, Vanessa Miller, Jane A Little

    High-risk SCD may be managed with chronic red blood cell exchange transfusions. We examined the prevalence of sleep-associated hypoxemia (≥5 minutes at SpO2 ≤88%) or nocturnal Hb desaturation (NHD) in chronically transfused adults with SCD. Of 41 identified participants, 15 (36.6%) had tested positive for NHD at some point prior to enrollment. The median duration of desaturation (SpO2 ≤88%) in those that tested positive was 88.3 minutes (IQR 27.9-226.0 minutes). Participants with and without NHD were compared using non-parametric statistical tests. Compared to participants without NHD, those with NHD had higher absolute reticulocyte counts (P = .018) and white blood counts (P = .05) and tended to be older. They had more anemia (P = .11) and higher lactate dehydrogenase levels (P = .072). Older age at initiation of chronic red blood cell transfusions associated the strongest with a longer duration of NHD (ρ = 0.4253, P = .0067), while prior history of cerebrovascular events associated with a shorter duration of NHD (P = .0315). Our results demonstrate that NHD is common in adults being treated with red blood cell exchange for high-risk SCD and associates with laboratory evidence of increased disease activity. Increased awareness of this complication and appropriate screening may provide an additional simple, low-cost, and physiologically relevant treatment intervention, that is oxygen therapy.

  • Open Access

    Cold comfort in sickle cell disease

    by Erica Sparkenbaugh, Jane Little

    In this issue of Blood, Ivy et al1 show that the alternative complement pathway drives vaso-occlusion and pain after cold exposure in a mouse model of sickle ce

  • Open Access

    RBC, heal thyself: PK activators in SCD

    by Jane A. Little

    In this issue of Blood, Xu et al1 open the hood of the sickle hemoglobin (HbS)–containing red blood cells (RBCs) and cleverly soup up the carburetor; that is, t